Navigation Links
Jazz Pharmaceuticals, Inc. Announces Board of Directors and Management Changes
Date:4/2/2009

PALO ALTO, Calif., April 2 /PRNewswire-FirstCall/ -- Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) today announced that Samuel R. Saks, its Chief Executive Officer and a member of its Board of Directors, has resigned from both positions, effective as of April 3, 2009. Dr. Saks will serve as a consultant to the company on medical and clinical matters after his departure.

"We thank Sam for his enormous contributions to Jazz Pharmaceuticals since its founding in 2003," said Bruce C. Cozadd, the company's Executive Chairman. "His dedication to patients, employees and our company culture has been an inspiration to all of us," he continued.

The Board of Directors has appointed Bruce C. Cozadd as the company's Chief Executive Officer. Mr. Cozadd has been Jazz Pharmaceuticals' Executive Chairman, and a member of the Board of Directors, since the company's founding in 2003. From 1991 until 2001, he held various positions with ALZA Corporation, a pharmaceutical company now owned by Johnson & Johnson, most recently as its Executive Vice President and Chief Operating Officer, with responsibility for research and development, manufacturing and sales and marketing. Previously at ALZA Corporation, he held the roles of Chief Financial Officer and Vice President, Corporate Planning and Analysis. Mr. Cozadd received a B.S. from Yale University and an M.B.A. from the Stanford Graduate School of Business. Mr. Cozadd serves on the boards of Cerus Corporation, a biopharmaceutical company; Threshold Pharmaceuticals, a biotechnology company; and The Nueva School and Stanford Hospital and Clinics, both non-profit organizations.

The Board of Directors has appointed Robert M. Myers, Jazz Pharmaceuticals' President, to the Board of Directors to fill the vacancy on the Board of Directors created by Dr. Saks' resignation. Mr. Myers joined Jazz Pharmaceuticals at its inception. He was appointed as Jazz Pharmaceuticals' President in March 2007. From 2003 until 2007, Mr. Myers served as Jazz Pharmaceuticals' Executive Vice President and Chief Business Officer. From 2002 until 2003, Mr. Myers served as Executive Vice President, Pharmaceuticals at Exelixis, Inc., a biotechnology company. He previously held various positions with ALZA Corporation from 1992 to 2001, most recently as its Senior Vice President, Commercial Development. In this role, he was responsible for ALZA Corporation's corporate development, mergers and acquisitions, new product planning and corporate planning. Mr. Myers received B.S. and M.S. degrees from Stanford University and an M.B.A. from the Stanford Graduate School of Business.

About Jazz Pharmaceuticals, Inc.

Jazz Pharmaceuticals is a specialty pharmaceutical company focused on identifying, developing and commercializing innovative products to meet unmet medical needs in neurology and psychiatry. For further information see www.JazzPharmaceuticals.com.


'/>"/>
SOURCE Jazz Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
2. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
3. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
4. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
5. Transcept Pharmaceuticals, Inc. to Present at 2007 BIO Investor Forum
6. ACG Announces Major Gift by Salix Pharmaceuticals, Inc.
7. Anthera Pharmaceuticals, Inc. Appoints Donald Santel to Board of Directors
8. Elan Pharmaceuticals, Inc. Licenses Software and Databases From GeneGo
9. Jazz Pharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results
10. Acura Pharmaceuticals, Inc. Announces Implementation of Reverse Stock Split and New Trading Symbol: ACPH
11. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) to be Presented at the Upcoming American Society of Hematology Meeting in Atlanta, Georgia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... December 07, 2016 , ... Maureen ... Program at Reproductive Medicine Associates of Connecticut (RMACT). McLaughlin brings nearly 20 years ... three acupuncturists to help patients realize their family building goals. Acupuncture helps ...
(Date:12/7/2016)... ... (PRWEB) December 07, 2016 , ... Angioma ... by cerebral cavernous angiomas, was awarded a grant from the Julian Grace Foundation ... New Mexico has more people with cavernous angioma than anywhere in the world. ...
(Date:12/6/2016)... (PRWEB) , ... December 06, 2016 , ... ... their brain networks that can be seen on a type of MRI, according ... is a progressive disorder of the central nervous system characterized by tremors or ...
(Date:12/6/2016)... ... , ... An inventor, from Talladega, Ala., thought there needed to be a ... SLING-VEST. , The SLING-VEST provides an effective way to support and align the arm ... a result, it helps to reduce discomfort and shifting. The invention features an effective ...
(Date:12/6/2016)... ... 2016 , ... In anticipation for the New Year, Dr. Mayoor Patel has ... courses in 2017, dentists of all levels can continue to advance the services offered ... attend a variety of continuing education courses each month on topics ranging from sleep ...
Breaking Medicine News(10 mins):
(Date:12/6/2016)... 6, 2016  Arcturus Therapeutics, Inc. ("Arcturus" or ... today that it entered into collaboration with Takeda ... the treatment of NASH and other gastrointestinal (GI) ... LUNAR™ and UNA Oligomer chemistry. The financial terms ... commitment to and expertise in GI disorders, we ...
(Date:12/6/2016)... 6, 2016 Breast Pump Market size is ... report by Global Market Insights, Inc. Continue Reading ... ... , , ... growing women employment rates and rising consumer awareness regarding importance of breast feeding ...
(Date:12/5/2016)... , Dec. 5, 2016  Balloon catheter is ... which is inserted into the femoral artery in the ... arm to treat constricted blood vessels. These products are ... to atherosclerosis – deposition of lipid substances in the ... catheter market is projected to expand at a CAGR ...
Breaking Medicine Technology: